0001415889-23-013048.txt : 20230906
0001415889-23-013048.hdr.sgml : 20230906
20230906190834
ACCESSION NUMBER: 0001415889-23-013048
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230715
FILED AS OF DATE: 20230906
DATE AS OF CHANGE: 20230906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Megna Michael R
CENTRAL INDEX KEY: 0001464583
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38492
FILM NUMBER: 231240631
MAIL ADDRESS:
STREET 1: 1050 HINGHAM STREET
CITY: ROCKLAND
STATE: MA
ZIP: 02370
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd.
CENTRAL INDEX KEY: 0001730430
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
BUSINESS PHONE: 7814399100
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
4
1
form4-09062023_110926.xml
X0508
4
2023-07-15
0001730430
Kiniksa Pharmaceuticals, Ltd.
KNSA
0001464583
Megna Michael R
C/O KINIKSA PHARMACEUTICALS, LTD.
CLARENDON HOUSE 2 CHURCH STREET
HAMILTON
D0
HM 11
BERMUDA
false
true
false
false
CHIEF ACCOUNTING OFFICER
0
Class A Common Share
2023-07-15
4
A
0
581
12.35
A
13558
D
Class A Common Share
2023-09-01
4
M
0
3933
A
17491
D
Class A Common Share
2023-09-01
4
F
0
1155
17.76
D
16336
D
Class A Common Share
2023-09-02
4
M
0
774
A
17110
D
Class A Common Share
2023-09-02
4
F
0
228
17.76
D
16882
D
Restricted Share Unit
2023-09-01
4
M
0
3933
0
D
Class A Common Share
3933
11797
D
Restricted Share Unit
2023-09-01
4
A
0
10230
0
A
Class A Common Share
10230
10230
D
Share Option
17.76
2023-09-01
4
A
0
20459
0
A
2033-08-31
Class A Common Share
20459
20459
D
Restricted Share Unit
2023-09-02
4
M
0
774
0
D
Class A Common Share
774
1549
D
The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2023 to July 15, 2023. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022.
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023.
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021.
/s/ Madelyn Zeylikman, Attorney-in-Fact
2023-09-06